Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Why Have the Hot Biotechs of a Year Ago Cooled Down?

This article was originally published in Start Up

Executive Summary

Most hot technologies have tended to fall into one of three categories: (i) incremental improvements that address a single segment of the drug discovery process but that fail to actually increase the number of clinical candidates produced by the drug discovery apparatus when considered as a whole; (ii) spellbinding technologies that have yet to show a practical, proven application to drug discovery; and (iii) technologies that are useful but that can't seem to be packaged within a successful corporate business model.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts